4-(4-(2,4-dibromo-6-methylphenoxy)quinazolin-2-ylamino)benzonitrile | 1172132-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(4-(2,4-dibromo-6-methylphenoxy)quinazolin-2-ylamino)benzonitrile
• 英文别名: 4-[[4-(2,4-dibromo-6-methylphenoxy)quinazolin-2-yl]amino]benzonitrile
• CAS: 1172132-09-0
• 化学式: C₂₂H₁₄Br₂N₄O
• 分子量: 510.187
• InChiKey: XZUJDDJHGBMMPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-chloro-4-(2,4-dibromo-6-methylphenoxy)quinazoline 、 对氨基苯腈 反应 2.0h， 生成 4-(4-(2,4-dibromo-6-methylphenoxy)quinazolin-2-ylamino)benzonitrile
  参考文献：
  名称：

  Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy

  摘要：

  Molecular hybridization of the known anti-HIV-1 template DPC083 and etravirine based on docking model overlay has been generated a novel series of diarylbenzopyrimidine analogues (DABPs) (5a-z). These new hybrids were assessed for their activity against HIV in MT-4 cell cultures. Most of these compounds showed good activity against wild-type HIV-1 and mutant viruses. In particular, compound 5r showed the most potent activity against wild-type HIV-1 with an EC50 value of 1.8 nM, and with a selectivity index up to 111,954. It also proved more active against mutant L100I, K103N, Y188L, and K103N + Y181C RT HIV-1 strains than efavirenz. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.05.081

文献信息

• PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
  申请人：Chen Fener

  公开号：US20120122902A1

  公开（公告）日：2012-05-17

  A pyrimidine derivative and the preparation method and usethereof. The said pyrimidine derivative is a diaryl pyrimidine derivative or a diaryl benzo pyrimidine derivative which has the structure shown as the Formula I and IV. Present pyrimidine derivative can be used for the prevention or the treatment of HIV.

  一种嘧啶衍生物及其制备方法和用途。所述的嘧啶衍生物是二芳基嘧啶衍生物或二芳基苯并嘧啶衍生物，其结构如公式I和IV所示。目前的嘧啶衍生物可用于预防或治疗HIV。
• US8809343B2
  申请人：——

  公开号：US8809343B2

  公开（公告）日：2014-08-19
• Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy
  作者：Zhao-Sen Zeng、Qiu-Qin He、Yong-Hong Liang、Xiao-Qing Feng、Fen-Er Chen、Erik De Clercq、Jan Balzarini、Christophe Pannecouque

  DOI：10.1016/j.bmc.2010.05.081

  日期：2010.7

  Molecular hybridization of the known anti-HIV-1 template DPC083 and etravirine based on docking model overlay has been generated a novel series of diarylbenzopyrimidine analogues (DABPs) (5a-z). These new hybrids were assessed for their activity against HIV in MT-4 cell cultures. Most of these compounds showed good activity against wild-type HIV-1 and mutant viruses. In particular, compound 5r showed the most potent activity against wild-type HIV-1 with an EC50 value of 1.8 nM, and with a selectivity index up to 111,954. It also proved more active against mutant L100I, K103N, Y188L, and K103N + Y181C RT HIV-1 strains than efavirenz. (C) 2010 Elsevier Ltd. All rights reserved.